Inorganic Nanoparticles Based Contrast Agents for X‐ray Computed Tomography

Jakhmola, Anshuman; Anton, Nicolas; Vandamme, Thierry F.

doi:10.1002/adhm.201200032

Cited by 154 publications

(121 citation statements)

References 163 publications

Supporting

Mentioning

120

Contrasting

Order By: Relevance

“…It has been a clinical tool for more than half a century and the first widespread clinical use of NPs as X-ray contrast agents in humans were 3 to 10-nm thorium dioxide nanoparticles [12,211]. However due to the long-term radiation effects and significant carcinogenicity of the 232 Th, its clinical application was rapidly given up.…”

Section: X-ray Imaging and Computed Tomography (Ct)mentioning

confidence: 99%

“…Functionalization can also help addressing NPs toxicity aspects [12,354,358,465,468,493,494]. Indeed, properly protected NPs conjugated or coated with biocompatible materials can be used for the fabrication of various functional systems with multimodality as well as targeting properties, reduced toxicity and proper removal from the body.…”

Section: Reaction Typementioning

confidence: 99%

“…They are used to improve the enhancement of image contrast as compared to molecular species and improve the visibility of features that would otherwise be difficult to detect. They go on receiving considerable attention in this field for their potential as contrast agents, [2][3][4][5][6][7][8][9] offering many advantages compared to more conventional chemical agents such as greater biocompatibility and reduced toxicity [8,[10][11][12][13].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Functionalized nanomaterials: their use as contrast agents in bioimaging: mono- and multimodal approaches

Trequesser¹,

Seznec²,

Delville³

2016

Nano Online

View full text Add to dashboard Cite

The successful development of nanomaterials illustrates the considerable interest in the development of new molecular probes for medical diagnosis and imaging. Substantial progress was made in synthesis protocol and characterization of these materials whereas toxicological issues are sometimes incomplete. Nanoparticle-based contrast agents tend to become efficient tools for enhancing medical diagnostics and surgery for a wide range of 2 imaging modalities. Multimodal nanoparticles (NPs) are much more efficient than conventional molecular-scale contrast agents. They provide new abilities for in vivo detection and enhanced targeting efficiencies through longer circulation times, designed clearance pathways, and multiple binding capacities. Properly protected, they can safely be used for the fabrication of various functional systems with targeting properties, reduced toxicity and proper removal from the body. This review mainly describes the advances in the development of mono-to multimodal NPs and their in vitro and in vivo relevant biomedical applications ranging from imaging and tracking to cancer treatment. Besides specific applications for classical imaging, (MRI, PET, CT, US, PAI) are also mentioned less common imaging techniques such as terahertz molecular imaging (THMI) or ion beam analysis (IBA).Perspectives on multimodal theranostic NPs and their potential for clinical advances are also mentioned.

show abstract

Section: X-ray Imaging and Computed Tomography (Ct)mentioning

confidence: 99%

Section: Reaction Typementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Functionalized nanomaterials: their use as contrast agents in bioimaging: mono- and multimodal approaches

Trequesser¹,

Seznec²,

Delville³

2016

Nano Online

View full text Add to dashboard Cite

show abstract

“…It has been a clinical tool for more than half a century, and the first widespread clinical use of NPs as X-ray CAs in humans were 3-to 10-nm thorium dioxide NPs [12,211] . However, due to the long-term radiation effects and significant carcinogenicity of the 232 Th, its clinical application was rapidly given up.…”

Section: X-ray Imaging and Computed Tomography (Ct)mentioning

confidence: 99%

“…Functionalization can also help in addressing NP toxicity aspects [12,354,358,465,468,493,494] . Indeed, properly protected NPs, conjugated or coated with biocompatible materials, can be used for the fabrication of various functional systems with multimodality as well as targeting properties, reduced toxicity, and proper removal from the body.…”

Section: Functionalizationmentioning

confidence: 99%

Functionalized nanomaterials: their use as contrast agents in bioimaging: mono- and multimodal approaches

Trequesser¹,

Seznec²,

Delville

2013

Nanotechnology Reviews

View full text Add to dashboard Cite

Abstract:The successful development of nanomaterials illustrates the considerable interest in the development of new molecular probes for medical diagnosis and imaging. Substantial progress was made in the synthesis protocol and characterization of these materials, whereas toxicological issues are sometimes incomplete. Nanoparticlebased contrast agents (CAs) tend to become efficient tools for enhancing medical diagnostics and surgery for a wide range of imaging modalities. The multimodal nanoparticles (NPs) are much more efficient than the conventional molecular-scale CAs. They provide new abilities for in vivo detection and enhanced targeting efficiencies through longer circulation times, designed clearance pathways, and multiple binding capacities. Properly protected, they can safely be used for the fabrication of various functional systems with targeting properties, reduced toxicity, and proper removal from the body. This review mainly describes the advances in the development of mono-to multimodal NPs and their in vitro and in vivo relevant biomedical applications ranging from imaging and tracking to cancer treatment. Besides the specific applications for classical imaging (magnetic resonance imaging, positron emission tomography, computed tomography, ultrasound, and photoacoustic imaging), the less common imaging techniques such as terahertz molecular imaging (THMI) or ion beam analysis (IBA) are mentioned. The perspectives on the multimodal theranostic NPs and their potential for clinical advances are also mentioned.

show abstract